Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The activation mutation JAK2 tyrosine kinase (JAK2V617F) is found in 50% of patients with myleofibrosis (MF). In this phase-2 study, CEP 701, a JAK2 inhibitor, was administered to MF patients harboring a JAK2 mutation.

Minimal Activity of the JAK2 Inhibitor CEP 701 in Myelofibrosis